Cargando…
Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review
BACKGROUND: Squamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539605/ https://www.ncbi.nlm.nih.gov/pubmed/37781197 http://dx.doi.org/10.3389/fonc.2023.1188772 |
_version_ | 1785113536924483584 |
---|---|
author | Zhang, Zhiqin Lin, Jiamao Yang, Linke Li, Yang |
author_facet | Zhang, Zhiqin Lin, Jiamao Yang, Linke Li, Yang |
author_sort | Zhang, Zhiqin |
collection | PubMed |
description | BACKGROUND: Squamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC patient who developed EGFR-T790M mutation and showed gefitinib resistance achieved an extremely long survival by taking Osimertinib alternatively. CASE SUMMARY: A patient, 66-year-old non-smoking and drinking male with advanced SCC who was deemed inoperable at the time of diagnosis. The first genetic testing showed deletion mutation of exon 19 of EGFR. The patient was then treated with gefitinib with no significant efficacy. EGFR-T790M mutation was found in the second genetic test. The treatment regimen was changed to radiotherapy with Osimertinib, and the patient’s primary lesion and the brain metastases were well controlled. CONCLUSION: This typical case highlights the important role of Osimertinib in patients with SCC carrying EGFR mutations. |
format | Online Article Text |
id | pubmed-10539605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105396052023-09-30 Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review Zhang, Zhiqin Lin, Jiamao Yang, Linke Li, Yang Front Oncol Oncology BACKGROUND: Squamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC patient who developed EGFR-T790M mutation and showed gefitinib resistance achieved an extremely long survival by taking Osimertinib alternatively. CASE SUMMARY: A patient, 66-year-old non-smoking and drinking male with advanced SCC who was deemed inoperable at the time of diagnosis. The first genetic testing showed deletion mutation of exon 19 of EGFR. The patient was then treated with gefitinib with no significant efficacy. EGFR-T790M mutation was found in the second genetic test. The treatment regimen was changed to radiotherapy with Osimertinib, and the patient’s primary lesion and the brain metastases were well controlled. CONCLUSION: This typical case highlights the important role of Osimertinib in patients with SCC carrying EGFR mutations. Frontiers Media S.A. 2023-09-14 /pmc/articles/PMC10539605/ /pubmed/37781197 http://dx.doi.org/10.3389/fonc.2023.1188772 Text en Copyright © 2023 Zhang, Lin, Yang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhang, Zhiqin Lin, Jiamao Yang, Linke Li, Yang Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
title | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
title_full | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
title_fullStr | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
title_full_unstemmed | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
title_short | Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
title_sort | osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539605/ https://www.ncbi.nlm.nih.gov/pubmed/37781197 http://dx.doi.org/10.3389/fonc.2023.1188772 |
work_keys_str_mv | AT zhangzhiqin osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT linjiamao osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT yanglinke osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview AT liyang osimertinibinhibitsbrainmetastasesandimproveslongtermsurvivalinapatientwithadvancedsquamouscelllungcanceracasereportandliteraturesreview |